Potential synergy of radiation therapy with vismodegib for basal cell carcinoma

JAMA Dermatology

Volumn 151, Issue 9, 2015, Pages 925-926

  Strasswimmer, John M ^a,b  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b BOCA RATON REGIONAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SONIC HEDGEHOG PROTEIN; VISMODEGIB; ANILIDE; PYRIDINE DERIVATIVE;

BASAL CELL CARCINOMA; BRACHYTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; DRUG SAFETY; EDITORIAL; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, BASAL CELL; MALE; SKIN NEOPLASMS; TUMOR RECURRENCE;

ANILIDES; CARCINOMA, BASAL CELL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; SKIN NEOPLASMS;

EID: 84941271260     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.0977     Document Type: Editorial

References (10)

1. Linos E, Schroeder SA, Chren MM. Potential overdiagnosis of basal cell carcinoma in older patients with limited life expectancy. JAMA. 2014; 312(10):997-998.
2. Pollom EL, Bui TT, Chang ALS, Colevas AD, Hara WY. Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma [published online April 15, 2015]. JAMA Dermatol. doi:10.1001/jamadermatol.2015.0326.
3. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
4. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J AmAcad Dermatol. 2014;70(1):60-69.
5. Alkeraye S, Maire C, Desmedt E, Templier C, Mortier L. Persistent alopecia induced by vismodegib. Br J Dermatol. 2014. doi:10.1111/bjd .13630.
6. Strasswimmer J, Latimer B, Ory S. Amenorrhea secondary to a vismodegib-induced blockade of follicle-stimulating hormone-receptor activation. Fertil Steril. 2014;102(2):555-557.
7. Ochoa B, Syn WK, Delgado I, et al. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology. 2010;51(5):1712-1723.
8. Alam M, Nanda S, Mittal BB, Kim NA, Yoo S. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J AmAcad Dermatol. 2011;65(2):377-388.
9. Gathings RM, Orscheln CS, Huang WW. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. J Am Acad Dermatol. 2014;70(4):e88-e89.
10. Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J AmAcad Dermatol. 2014;71(5):904.e1-911.e1.